Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum toxin vaccine - DynPort

Drug Profile

Botulinum toxin vaccine - DynPort

Alternative Names: Botulism vaccine - DynPort; rBV A/B; recombinant botulinum neurotoxin vaccine; Recombinant botulinum vaccine A/B

Latest Information Update: 18 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DynPort Vaccine Company LLC; United States Army Medical Research Institute of Infectious Diseases
  • Developer DynPort Vaccine Company
  • Class Bacterial vaccines
  • Mechanism of Action Botulinum toxin inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Botulism

Most Recent Events

  • 04 Dec 2018 DynPort withdraws a phase III trial in healthy volunteers in Botulism (Prevention) in USA, prior to enrolment (IM) (NCT01940315)
  • 24 Oct 2018 DynPort plans to re-initiate a phase III trial in healthy volunteers in Botulism (Prevention) in USA (IM) (NCT01940315)
  • 09 Oct 2018 Botulinum toxin vaccine is still in phase II trials for Botulism (Prevention) in the US (NCT03676634)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top